IART Quote, Financials, Valuation and Earnings

Paragon 28 has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of -15.5%. Integra Lifesciences Holdings's return on equity of -0.45% beat Paragon 28's return on equity of -36.38%.

Integra Lifesciences Holdings has a consensus price target of $26.25, signalling upside risk potential of 16.72%. On the other hand Paragon 28 has an analysts' consensus of $14.50 which suggests that it could grow by 11.45%. Given that Integra Lifesciences Holdings has higher upside potential than Paragon 28, analysts believe Integra Lifesciences Holdings is more attractive than Paragon 28.

Integra Lifesciences Holdings has a beta of 1.229, which suggesting that the stock is 22.861% more volatile than S&P 500. In comparison Paragon 28 has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Paragon 28 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Paragon 28 pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are larger than Paragon 28 quarterly revenues of $71.7M. Integra Lifesciences Holdings's net income of $19.4M is higher than Paragon 28's net income of -$11.1M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Paragon 28's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.08x versus 4.23x for Paragon 28. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of -13.52%. Integra Lifesciences Holdings's return on equity of -0.45% beat Orthofix Medical's return on equity of -22.96%.

Integra Lifesciences Holdings has a consensus price target of $26.25, signalling upside risk potential of 16.72%. On the other hand Orthofix Medical has an analysts' consensus of $24.30 which suggests that it could grow by 46.12%. Given that Orthofix Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Orthofix Medical is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.229, which suggesting that the stock is 22.861% more volatile than S&P 500. In comparison Orthofix Medical has a beta of 1.058, suggesting its more volatile than the S&P 500 by 5.812%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Orthofix Medical pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are larger than Orthofix Medical quarterly revenues of $215.7M. Integra Lifesciences Holdings's net income of $19.4M is higher than Orthofix Medical's net income of -$29.1M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Orthofix Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.08x versus 0.80x for Orthofix Medical. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of 26.88%. Integra Lifesciences Holdings's return on equity of -0.45% beat ResMed's return on equity of 25.56%.

Integra Lifesciences Holdings has a consensus price target of $26.25, signalling upside risk potential of 16.72%. On the other hand ResMed has an analysts' consensus of $270.09 which suggests that it could grow by 22.94%. Given that ResMed has higher upside potential than Integra Lifesciences Holdings, analysts believe ResMed is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.229, which suggesting that the stock is 22.861% more volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are smaller than ResMed quarterly revenues of $1.3B. Integra Lifesciences Holdings's net income of $19.4M is lower than ResMed's net income of $344.6M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.08x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 4.39% compared to Integra Lifesciences Holdings's net margin of -10.04%. Integra Lifesciences Holdings's return on equity of -0.45% beat Xtant Medical Holdings's return on equity of -35.34%.

Integra Lifesciences Holdings has a consensus price target of $26.25, signalling upside risk potential of 16.72%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 224.07%. Given that Xtant Medical Holdings has higher upside potential than Integra Lifesciences Holdings, analysts believe Xtant Medical Holdings is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.229, which suggesting that the stock is 22.861% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $442.6M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Integra Lifesciences Holdings's net income of $19.4M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.08x versus 0.62x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.